Cynosure Inc. Stock Upgraded (CYNO)

NEW YORK ( TheStreet) -- Cynosure (Nasdaq: CYNO) has been upgraded by TheStreet Ratings from hold to buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, impressive record of earnings per share growth and compelling growth in net income. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results.

Highlights from the ratings report include:
  • CYNO's very impressive revenue growth greatly exceeded the industry average of 7.5%. Since the same quarter one year prior, revenues leaped by 52.6%. Growth in the company's revenue appears to have helped boost the earnings per share.
  • CYNO's debt-to-equity ratio is very low at 0.01 and is currently below that of the industry average, implying that there has been very successful management of debt levels. Along with this, the company maintains a quick ratio of 2.61, which clearly demonstrates the ability to cover short-term cash needs.
  • Powered by its strong earnings growth of 233.33% and other important driving factors, this stock has surged by 37.57% over the past year, outperforming the rise in the S&P 500 Index during the same period. Regarding the stock's future course, although almost any stock can fall in a broad market decline, CYNO should continue to move higher despite the fact that it has already enjoyed a very nice gain in the past year.
  • CYNOSURE INC reported significant earnings per share improvement in the most recent quarter compared to the same quarter a year ago. The company has demonstrated a pattern of positive earnings per share growth over the past two years. We feel that this trend should continue. During the past fiscal year, CYNOSURE INC continued to lose money by earning -$0.23 versus -$0.44 in the prior year. This year, the market expects an improvement in earnings ($0.17 versus -$0.23).
  • The net income growth from the same quarter one year ago has significantly exceeded that of the S&P 500 and the Health Care Equipment & Supplies industry. The net income increased by 235.8% when compared to the same quarter one year prior, rising from -$0.80 million to $1.08 million.
.

Cynosure, Inc. develops, manufactures, and markets aesthetic treatment systems to the dermatology, plastic surgery, and general medical markets. Cynosure has a market cap of $121.4 million and is part of the health care sector and health services industry. Shares are up 39.8% year to date as of the close of trading on Wednesday.

You can view the full Cynosure Ratings Report or get investment ideas from our investment research center.
-- Written by a member of TheStreet RatingsStaff
null

If you liked this article you might like

Medtronic Earnings Rebound in Third Quarter, Shares Climb

Deals of the Week: Valentine Couplings and Breakups

Wall Street Smashes Records for Fourth Day in a Row After Rocky Session

Stocks Find Upward Momentum Again as Chances of a Rate Hike Rise

Stocks Mixed as Fed's Yellen Talks Rates on Capitol Hill